Abstract：Objective To investigate the clinical effect of Pitavastatin Calcium Tablets combined with Aspirin in the treatment of coronary heart disease with hyperlipidemia. Methods Altogether 93 patients who had coronary heart disease with hyperlipidemia treated in Dexing People′s Hospital from March 2018 to February 2020 were selected as subjects and divided into control group (n=46) and observation group (n=47) according to the blind drawing method. The two groups were given conventional treatment, the control group was treated with Pitavastatin Calcium Tablets, while the observation group was treated with Aspirin on the basis of the control group. The clinical efficacy, blood lipid indexes and total incidence of adverse reactions were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group, and the total effective rate of the observation group(97.87%) was higher than that of the control group (82.61%), with statistically significant differences (P<0.05). After treatment, the levels of total cholesterol (TC) ([1.56±0.37] mmol/L), triacylglycerol (TG) ([3.13±0.54] mmol/L), low density lipoprotein cholesterol (LDL-C) ([2.19±0.36] mmol/L) in the observation group were lower than those before treatment ([4.38±1.01], [6.49±1.52], [5.24±1.01] mmol/L), the differences were statistically significant (P<0.05). The levels of TC ([2.31±0.47] mmol/L), TG ([4.61±0.98] mmol/L), LDL-C ([3.28±0.49] mmol/L) in the control group after treatment were lower than those before treatment ([4.36±1.03], [6.51±1.48], [5.33±1.05] mmol/L), the differences were statistically significant (P<0.05). The high density lipoprotein cholesterol (HDL-C) of the observation group after treatment was(2.03±0.34) mmol/L, which was higher than that before treatment ([0.86±0.13] mmol/L), the HDL-C of the control group after treatment was (1.56±0.28) mmol/L, which was higher than that before treatment ([0.85±0.12] mmol/L), the differences were statistically significant (P<0.05). And the levels of TC, TG and LDL-C of the observation group after treatment were lower than those of the control group, the HDL-C level of the observation group was higher than that of the control group, the differences were statistically significant (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the observation group (6.38%) and control group (13.04%) (P>0.05). Conclusion Pitavastatin Calcium Tablets combined with Aspirin has a significant effect in the treatment of coronary heart disease patients with hyperlipidemia, which can effectively improve patients′ blood lipid index, promote their physical recovery, and have high safety.
童早英. 匹伐他汀钙片联合阿司匹林治疗冠心病高脂血症的临床效果[J]. 中国当代医药, 2021, 28(3): 83-86.
TONG Zao-ying. Clinical effect of Pitavastatin Calcium Tablets combined with Aspirin in the treatment of coronary heart disease with hyperlipidemia. 中国当代医药, 2021, 28(3): 83-86.
京公网安备 11010502046607号